

CLAIMS

1. The use of a compound comprising one or more sugar moieties, which optionally are aminosubstitutes, and possibly other moieties, wherein said compound is a molecule comprising at least two aminosubstituents, said aminosubstituents being primary, secondary or tertiary amino groups, wherein said aminosubstituents are either attached to one single sugar moiety or attached to several sugar moieties or other moieties of the molecule, or to chains connecting two moieties or to chains being substituents to the molecule, for the manufacture of a pharmaceutical preparation useful as an agent capable of influencing an amine oxidase enzyme activity.
2. The use according to claim 1, wherein the aminosubstituents are primary amino substituents (NH_2 -groups) either attached to one single sugar moiety or attached to several sugar moieties or other moieties of the molecule.
3. The use according to claim 1 or 2 wherein the molecule comprises several sugar moieties and/or other moieties.
4. The use according to claim 1, 2 or 3, wherein the compound is an aminoglycoside, especially an aminoglycoside antibiotic.
5. The use of a compound as defined in any of the claims 1-4 for the manufacture of a pharmaceutical preparation for treatment or prevention of a disease or condition benefiting from inhibiting an amine oxidase enzyme, wherein the disease or condition is an inflammatory disease or condition; a disease related to carbohydrate metabolism; a disease related to aberrations in adipocyte differentiation or function or smooth muscle cell function; or a vascular disease.
6. The use according to claim 5 wherein said inflammatory disease or condition is a connective tissue inflammatory disease or condition.

7. The use according to claim 6, wherein said connective tissue inflammatory disease or condition is selected from the group consisting of ankylosing spondylitis, Reiter's syndrome, psoriatic arthritis, osteoarthritis or degenerative joint disease, rheumatoid arthritis, Sjögren's syndrome, Bechet's syndrome, relapsing
- 5 polychondritis, systemic lupus erythematosus, discoid lupus erythematosus, systemic sclerosis, eosinophilic fasciitis, polymyositis and dermatomyositis, polymyalgia rheumatica, vasculitis, temporal arteritis, polyarteritis nodosa, Wegner's granulomatosis, mixed connective tissue disease, and juvenile rheumatoid arthritis.
- 10
8. The use according to claim 5 wherein said inflammatory disease or condition is a gastrointestinal inflammatory disease or condition.
9. The use according to claim 8 wherein the gastrointestinal inflammatory disease or
- 15 condition is selected from the group consisting of Crohn's disease, ulcerative colitis, irritable bowel syndrome (spastic colon), fibrotic conditions of the liver, inflammation of the oral mucosa (stomatitis), and recurrent aphthous stomatitis.
10. The use according to claim 5 wherein said inflammatory disease or condition is
- 20 a central nervous system inflammatory disease or condition.
11. The use according to claim 11, wherein said central nervous system inflammatory disease or condition is selected from the group consisting of multiple sclerosis, Alzheimer's disease, and ischemia-reperfusion injury associated with
- 25 ischemic stroke.
12. The use according to claim 5 wherein said inflammatory disease or condition is a pulmonary inflammatory disease or condition.
13. The use according to claim 12, wherein said pulmonary inflammation disease or
- 30 condition is selected from the group consisting of asthma, chronic obstructive pulmonary disease, and adult respiratory distress syndrome.

14. The use according to claim 5, wherein said inflammatory disease or condition is a skin inflammatory disease or condition.
- 5 15. The use according to claim 14, wherein said skin inflammatory disease or condition is selected from the group consisting of contact dermatitis, atopic dermatitis, psoriasis, pityriasis rosea, lichen planus, and pityriasis rubra pilaris.
16. The use according to claim 5, wherein the inflammatory condition is related to
10 tissue trauma or resulting from organ transplantations or other surgical operations.
17. The use according to claim 5, wherein said disease related to carbohydrate metabolism is selected from the group consisting of diabetes, atherosclerosis, vascular retinopathies, retinopathy, nephropathy, nephrotic syndrome,
15 polyneuropathy, mononeuropathies, autonomic neuropathy, foot ulcers or joint problems.
18. The use according to claim 5, wherein said disease relating to aberrations in adipocyte differentiation or function or smooth muscle cell function is selected from
20 the group consisting of atherosclerosis and obesity.
19. The use according to claim 5, wherein said vascular disease is selected from the group consisting of atheromatous atherosclerosis, nonatheromatous atherosclerosis, ischemic heart disease, peripheral arterial occlusion, thromboangiitis obliterans
25 (Buerger's disease), and Raynaud's disease and phenomenon.